Furthermore, the decreased amount of CD8+ tumor-infiltrating lymphocytes in patients with EC and MSH deficiency or Nectin-4 overexpression is thought to provide important clues for screening and monitoring patients responding to cancer immunotherapy. This evidence concerns the gene CD8A and neoplasm.